【摘要】 目的探讨罗格列酮联合胰岛素治疗2型糖尿病的治疗效果。方法42例2型糖尿病患者随机分为:胰岛素组(Ins),n=21;罗格列酮联合胰岛素组(Ins+Ros),n=21。Ins组采用诺和灵R于早、中、晚三餐前及诺和灵N睡前皮下注射治疗;Ins+Ros组加用罗格列酮,4mg/d,并根据血糖水平调整用量4～8mg/d,治疗16周。两组患者于治疗前、治疗后测BMI、FPG、2hPG、HbA1c、FCP、TC、TG、LDL-C、HDL-C等指标,两组进行对比。结果Ins+Ros组FPG、2hPG、HbA1c、TG、TC、LDL-C等和治疗前及Ins组治疗后相比均明显下降(P<0.05),BMI、FCP等和治疗前及组间对比均无统计学差异(P>0.05)。结论罗格列酮在治疗2型糖尿病过程中,可以明显改善胰岛素抵抗,降低血糖、血脂,在临床中联合使用胰岛素进行治疗,可以更好的促进2型糖尿病患者的康复。更多还原

【Abstract】 Objective To discover clinic effect on T2-DM utilizing rosiglitazone associated with insulin. Methods 42 T2-DM patients were divided into two groups:Ins group,n=21;Ins+Ros group,n=21. In Ins group,Novolin R was hypodemic injected before three meals and Novolin N before retiring;In Ins+Ros group,rosiglitazone was added with 4mg/d,justified from 4-8mg/d. Time of therapy was 16 weeks. Index of BMI,FPG,2hPG were measured pro-therapy and post-therapy. Results In Ins+Ros group,index of FPG,2hPG,HbA1c,TG,TC,LDL-C descended obviously compared with pro-therapy and Ins group post-therapy(P<0.05),Index of BMI,FCP changed slightly(P>0.05). Conclusions Rosiglitazone can heal insulin resistance obviously and lower blood sugar,blood fat,and it can improve T2-DM patients treatment.更多还原